DNDi: 100 years of Chagas disease, but R&D still lacking
This article was originally published in Scrip
On the 100th anniversary of the discovery of Chagas disease, a new global campaign to encourage awareness and research has been launched by the Drugs for Neglected Disease initiative (DNDi). The disease, which was discovered in 1909 by the Brazilian doctor Carlos Chagas, is caused by the parasite Trypanosoma cruzi, which is transmitted to humans by the triatomine bugs which can hide in the cracks of poorly built homes.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).